Benjamin L. L. Clayton

Benjamin L. L. Clayton

Auto-generated profile, based on publicly available information

Benjamin L. L. Clayton

Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MMMayur Madhavan
Mayur Madhavan
ZNZachary S. Nevin
Zachary S. Nevin
HSH. Elizabeth Shick
H. Elizabeth Shick
EGEric Garrison
Eric Garrison
CCCheryl Clarkson-Paredes
Cheryl Clarkson-Paredes
PTPaul J. Tesar
Paul J. Tesar

1 January 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
APAya D. Pusic
Aya D. Pusic
KPKae M. Pusic
Kae M. Pusic
BCBenjamin L.L. Clayton
Benjamin L.L. Clayton
RKRichard P. Kraig
Richard P. Kraig

3 August 2016 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
PRPierre De Rossi
Pierre De Rossi
VBVirginie Buggia-Prévot
Virginie Buggia-Prévot
BCBenjamin L. L. Clayton
Benjamin L. L. Clayton
JVJared B. Vasquez
Jared B. Vasquez
CSCarson van Sanford
Carson van Sanford
GTGopal Thinakaran
Gopal Thinakaran
Background: Genome-wide association studies have identified BIN1 within the second most significant susceptibility locus in late-onset Alzheimer’s disease (AD). BIN1 undergoes complex alternative splicing to generate multiple isoforms with diverse functions in multiple cellular processes including endocytosis and membrane remodeling. An increase in BIN1 expression in AD and an interaction between BIN1 and Tau have been reported. However, disparate descriptions of BIN1 expression and localization in the brain previously reported in the literature and the lack of clarity on brain BIN1 isoforms present formidable challenges to our understanding of how genetic variants in BIN1 increase the risk for AD. Methods: In this study, we analyzed BIN1 mRNA and protein levels in human brain samples from individuals with or without AD. In addition, we characterized the BIN1 expression and isoform diversity in human and rodent tissue by immunohistochemistry and immunoblotting using a panel of BIN1 antibodies. Results: Here, we report on BIN1 isoform diversity in the human brain and document alterations in the levels of select BIN1 isoforms in individuals with AD. In addition, we report striking BIN1 localization to white matter tracts in rodent and the human brain, and document that the large majority of BIN1 is expressed in mature oligodendrocytes whereas neuronal BIN1 represents a minor fraction. This predominant non-neuronal BIN1 localization contrasts with the strict neuronal expression and presynaptic localization of the BIN1 paralog, Amphiphysin 1. We also observe upregulation of BIN1 at the onset of postnatal myelination in the brain and during differentiation of cultured oligodendrocytes. Finally, we document that the loss of BIN1 significantly correlates with the extent of demyelination in multiple sclerosis lesions. Conclusion: Our study provides new insights into the brain distribution and cellular expression of an important risk factor associated with late-onset AD. We propose that efforts to define how genetic variants in BIN1 elevate the risk for AD would behoove to consider BIN1 function in the context of its main expression in mature oligodendrocytes and the potential for a role of BIN1 in the membrane remodeling that accompanies the process of myelination.

3 April 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
WLWensheng Lin
Wensheng Lin
YLYifeng Lin
Yifeng Lin
JLJin Li
Jin Li
AFAli G. Fenstermaker
Ali G. Fenstermaker
SWSharon W. Way
Sharon W. Way
BPBrian Popko
Brian Popko
There is compelling evidence that oligodendrocyte apoptosis, in response to CNS inflammation, contributes significantly to the development of the demyelinating disorder multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). Therefore, approaches designed to protect oligodendrocytes would likely have therapeutic value. Activation of pancreatic endoplasmic reticulum kinase (PERK) signaling in response to endoplasmic reticulum (ER) stress increases cell survival under various cytotoxic conditions. Moreover, there is evidence that PERK signaling is activated in oligodendrocytes within demyelinating lesions in multiple sclerosis and EAE. Our previous study demonstrated that CNS delivery of the inflammatory cytokine interferon-γ before EAE onset protected mice against EAE, and this protection was dependent on PERK signaling. In our current study, we sought to elucidate the role of PERK signaling in oligodendrocytes during EAE. We generated transgenic mice that allow for temporally controlled activation of PERK signaling, in the absence of ER stress, specifically in oligodendrocytes. We demonstrated that persistent activation of PERK signaling was not deleterious to oligodendrocyte viability or the myelin of adult animals. Importantly, we found that enhanced activation of PERK signaling specifically in oligodendrocytes significantly attenuated EAE disease severity, which was associated with reduced oligodendrocyte apoptosis, demyelination, and axonal degeneration. This effect was not the result of an altered degree of the inflammatory response in EAE mice. Our results provide direct evidence that activation of PERK signaling in oligodendrocytes is cytoprotective, protecting mice against EAE.

13 March 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWSharon W. Way
Sharon W. Way
JPJoseph R. Podojil
Joseph R. Podojil
BCBenjamin L. Clayton
Benjamin L. Clayton
AZAnita Zaremba
Anita Zaremba
TCTassie L. Collins
Tassie L. Collins
BPBrian Popko
Brian Popko
Oligodendrocyte death contributes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS). Nevertheless, current MS therapies are mainly immunomodulatory and have demonstrated limited ability to inhibit MS progression. Protection of oligodendrocytes is therefore a desirable strategy for alleviating disease. Here we demonstrate that enhancement of the integrated stress response using the FDA-approved drug guanabenz increases oligodendrocyte survival in culture and prevents hypomyelination in cerebellar explants in the presence of interferon-γ, a pro-inflammatory cytokine implicated in MS pathogenesis.In vivo, guanabenz treatment protects against oligodendrocyte loss caused by CNS-specific expression of interferon-γ. In a mouse model of MS, experimental autoimmune encephalomyelitis, guanabenz alleviates clinical symptoms, which correlates with increased oligodendrocyte survival and diminished CNS CD4+ T cell accumulation. Moreover, guanabenz ameliorates relapse in relapsing-remitting experimental autoimmune encephalomyelitis. Our results provide support for a MS therapy that enhances the integrated stress response to protect oligodendrocytes against the inflammatory CNS environment.

1 October 2016 in Brain Research
Verified
Journal Article
Closed access
BCBenjamin L.L. Clayton
Benjamin L.L. Clayton
BPBrian Popko
Brian Popko